The biotechnology sector is at a critical turning point, marked by deep structural and technological challenges. The "patent cliff" continues to threaten industry revenues, with an estimated potential loss of $400 billion. Concurrently, the integration of artificial intelligence (AI) into research and development (R&D) processes is emerging as an essential solution to maintain competitiveness. Recent advancements, such as Insilico Medicine's use of AI to drastically reduce drug development timelines in China, illustrate the transformative potential of these technologies. However, they also raise security and ethical questions, particularly regarding intellectual property and cyber risks.